Biotech | August 24, 2021
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
This is the first of its kind vaccine for Covid 19 to get the go-ahead
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Subscribe To Our Newsletter & Stay Updated
